CHICAGO, Jan. 8 /PRNewswire/ -- Ruder Finn, a leading global communications, counseling and services agency, today announced that it has been named the agency of record for Efoora. The Buffalo Grove, IL-based, fast-growing developer of rapid, diagnostic products is best known for its strides in disease tests (including Mad Cow and Chronic Wasting rapid tests), rapid HIV testing, and its innovative, patent protected PRIMOS blood glucose monitoring platform.
The agency has been engaged to develop and implement a comprehensive communications program that will focus primarily on three significant products expected to receive approval from the United States Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) within the next six months.
"Ruder Finn has both an excellent reputation and a proven ability to generate impressive communications results," said David Grosky, chairman of the board of directors and chief executive officer of Efoora. "They offer a tremendous amount of experience and expertise in the biotech and healthcare arenas, and we expect them to play a significant role in helping us expand awareness of our products and technology platforms."
Ruder Finn's Chicago and Los Angeles offices will jointly service the account. Howard Solomon, executive vice president, U.S. regional operations for Ruder Finn in Chicago, and healthcare industry veteran Kathy Vincent, vice president, will co-head the team.
"Efoora is widely regarded as one of the top emerging biotech players in the Midwest, and we feel very good about the company's business prospects," said Solomon. "Our communications efforts will play a very important role for Efoora in the next 12 months, which will without question be a milestone year for the company. Furthermore, this account is particularly strategic for our Chicago office as we look to capitalize on the Midwest's growing biotech market."
Efoora is a proprietary developer of rapid, diagnostic tests. Efoora's flagship test, the Efoora rapid HIV test is an immunochromatographic assay that detects the presence of circulating human antibodies to the HIV-1 and HIV-2 virus in whole blood, serum, and plasma. It provides the end user a method of screening a specimen for the presence of these antibodies as an indication of exposure to the virus in less than 30 minutes where other FDA-approved screening assays give results in 2-4 hours. In addition, Efoora develops and optimizes other rapid tests for several outside biodiagnostic companies. Efoora has a world class R&D scientific team made up of scientists from several major diagnostic companies. Efoora will continue to develop additional proprietary rapid tests on additional disease states as well as continue to build its third party development relationships.
About Ruder Finn
Ruder Finn is a leading communications, counseling and services Agency with more than 55 years' experience. The Ruder Finn Group maintains offices in New York, Boston, Chicago, Los Angeles, San Francisco, Washington, D.C. London, Paris, Jerusalem, Beijing, Guangzhou, Hong Kong, Shanghai, Singapore and Sydney. The Agency also works with affiliates in major markets throughout the U.S., Europe and Latin America. Ruder Finn recently ranked No. 1 in New York in revenues and staff size by O'Dwyer's Ranking for 2002, serves the global and local communications needs of more than 250 corporations and nonprofit organizations. Additional information about Ruder Finn can be found on the company's Web site (http://www.ruderfinn.com/).